Single-Use Bioprocessing Market Accelerates as Biopharmaceutical Manufacturers Embrace Disposable Technologies

Biopharmaceutical manufacturers worldwide are rapidly shifting away from traditional stainless-steel production systems toward disposable technologies that reduce contamination risk and improve manufacturing flexibility. A detailed analysis of the single-use bioprocessing market shows global revenue climbing from an estimated USD 21.01 billion in 2024 to USD 54.40 billion by 2031, representing a compound annual growth rate of 14.56% throughout the forecast period. Valued at USD 18.65 billion in 2023, the market's rapid expansion reflects surging demand for cost-effective, scalable production solutions across vaccines, cell and gene therapies, and monoclonal antibody manufacturing.

What Single-Use Bioprocessing Involves

Single-use bioprocessing relies on disposable, pre-sterilized components such as bioreactors, filtration systems, storage bags, and tubing that are used for a single production cycle before being discarded. This eliminates the need for extensive cleaning, sterilization, and validation associated with reusable stainless-steel equipment. The approach delivers several operational advantages, including reduced contamination risk, lower capital and operational costs, faster changeover between production runs, and greater manufacturing flexibility, all of which have made single-use systems the preferred choice for many biomanufacturers, particularly those producing vaccines, cell therapies, and biologics.

Market Overview

Growth in the single-use bioprocessing space is being driven by a combination of factors, including advancements in biopharmaceutical manufacturing techniques, rising government investment in biomanufacturing infrastructure, and an expanding biopharmaceutical sector overall. Major companies operating across this landscape include DH Life Sciences, LLC, Merck KGaA, Thermo Fisher Scientific Inc., Saint-Gobain, Sartorius AG, 3M, Eaton, ALFA LAVAL, Lonza Group Ltd., Entegris, Parker Hannifin Corp., Avantor Inc., PBS Biotech Inc., Meissner Filtration Products, and Eppendorf SE.

Rising chronic disease prevalence is a significant contributor to market expansion. Cancer registry data from Spain, for instance, recorded approximately 279,260 new cancer cases in 2023, with colorectal, lung, and urinary bladder cancers among the most prevalent diagnoses. This growing disease burden is intensifying demand for innovative treatments and driving greater reliance on single-use technologies throughout the drug development pipeline.

Investment in Cell Therapy Driving Growth

The expansion of cell therapy production capacity represents one of the most powerful growth drivers for single-use bioprocessing. CAR-T cell therapies and stem cell treatments have attracted substantial investment from both private and public sectors, with companies increasingly leveraging single-use technologies to achieve cost-effective scalability. According to Global Genes, 76 cell and gene therapies had been launched worldwide as of 2023, more than double the number recorded a decade earlier, while spending on cell and gene therapies reached USD 5.9 billion in 2023, a 38% increase from the prior year.

High Initial Investment Remains a Key Challenge

Despite strong long-term growth prospects, the high upfront investment required to establish single-use bioprocessing systems continues to pose a barrier, particularly for smaller companies with limited financial resources. Many organizations are addressing this challenge through phased adoption strategies that integrate single-use technologies gradually, helping manage capital expenditure while still capturing operational benefits. Vendors, meanwhile, are working to improve system cost-efficiency and offer more flexible financing arrangements to broaden accessibility across the biomanufacturing sector.

Mitigating Cross-Contamination Risk

A defining trend in the market is the accelerating adoption of single-use technologies specifically to reduce cross-contamination risk in biopharmaceutical production. In April 2023, Cytiva introduced its X-platform bioreactors, engineered to optimize single-use upstream bioprocessing through improved production capabilities, ergonomic design, and streamlined supply chain integration. This kind of innovation allows manufacturers to respond more quickly to shifting market demands and production schedules, enhancing overall operational efficiency.

Market Segmentation

By product, the market spans bioreactors, tubing and connectors, bags and bottles, pumps and filters, and other categories. Bags and bottles generated the largest share of revenue in 2023, at USD 6.64 billion, owing to their cost-effectiveness, flexibility in handling varying production volumes, and ability to minimize contamination risk. By application, upstream processing held a 42.21% share of the market in 2023, reflecting its critical role in early-stage biopharmaceutical production, including cell culture, media preparation, and fermentation. By end-user, biopharmaceutical manufacturers represent the largest segment, projected to reach USD 25.94 billion by 2031 as demand for scalable, cost-efficient production solutions continues to rise.

Regional Analysis

North America led the global single-use bioprocessing market in 2023, capturing a 36.74% share worth USD 6.85 billion. This leadership position reflects substantial research and development spending, the presence of large-scale manufacturing operations, and a well-established biopharmaceutical sector across the region. In June 2023, the Canadian government announced an investment of approximately USD 2.1 billion across 36 biomanufacturing, vaccine, and therapeutics initiatives spanning multiple provinces, a move designed to strengthen the country's pandemic response capacity and life sciences innovation ecosystem.

Asia Pacific is projected to register the fastest growth over the forecast period, with a CAGR of 16.46%, driven by rapid advancements in biomanufacturing technology, rising biopharmaceutical demand linked to chronic disease prevalence, and strong government support for the life sciences sector. Expanding healthcare infrastructure and growing adoption of cost-effective, scalable production solutions further reinforce the region's growth trajectory.

Regulatory Framework

In the United States, the Food and Drug Administration oversees single-use bioprocessing systems through its Current Good Manufacturing Practice regulations, covering equipment design, validation, and maintenance requirements. In the United Kingdom, the Medicines and Healthcare Products Regulatory Agency enforces compliance with Good Manufacturing Practice guidelines. China's National Medical Products Administration regulates single-use bioprocessing technologies under its own Good Manufacturing Practice standards, while India's Central Drugs Standard Control Organization enforces requirements under the Drugs and Cosmetics Act. In Japan, the Pharmaceuticals and Medical Devices Agency oversees compliance with Japanese GMP guidelines covering equipment used in biologics production.

Competitive Landscape

The single-use bioprocessing industry features a mix of established multinational corporations and specialized biotechnology suppliers, all competing through product innovation and sustained research and development investment. In April 2024, SaniSure introduced Fill4Sure, a tailored single-use filling assembly designed to accelerate drug time-to-market while enhancing security and repeatability during the fill-finish process, addressing longstanding cost and speed challenges within the industry.

Leading companies in this space include DH Life Sciences, LLC, Merck KGaA, Thermo Fisher Scientific Inc., Saint-Gobain, Sartorius AG, 3M, Eaton, ALFA LAVAL, Lonza Group Ltd., Entegris, Parker Hannifin Corp., Avantor Inc., PBS Biotech Inc., Meissner Filtration Products, and Eppendorf SE.

Recent Developments

In June 2024, Thermo Fisher Scientific Inc. introduced biobased films expanding its Aegis and CX film offerings, using plant-based materials to lower the carbon footprint of single-use bioprocessing containers. In April 2024, Cytiva launched its Xcellerex magnetic mixer, a single-use mixing system built to address large-scale manufacturing challenges for monoclonal antibodies, vaccines, and genomic medicines. Merck introduced its Ultimus Single-Use Process Container Film in April 2023, featuring a woven nylon structure that delivers superior durability and leak resistance. Getinge unveiled its AppliFlex ST GMP single-use bioreactor system in September 2023, designed to bridge research and clinical production for cell and gene therapy applications.

Investment and Strategic Implications

Biopharmaceutical manufacturers evaluating capital investment decisions face a growing incentive to transition toward single-use systems, particularly as production shifts toward smaller-batch, higher-value therapeutics such as cell and gene therapies where flexibility and rapid changeover matter more than the massive scale economics of traditional stainless-steel bioreactors. Contract development and manufacturing organizations, in particular, benefit from the ability to reconfigure production lines quickly between different client programs without the extensive cleaning validation required by fixed equipment.

Suppliers that can offer integrated, end-to-end single-use platforms spanning upstream and downstream processing are likely to capture greater customer loyalty than those offering standalone components, as biomanufacturers increasingly value simplified supply chains and reduced integration risk. Given the high upfront investment barrier facing smaller biotech companies, vendors offering flexible financing, modular scale-up pathways, and rental or leasing arrangements are well positioned to expand their addressable customer base beyond large pharmaceutical companies into the broader emerging biotech ecosystem.

Key Market Takeaways

• Global single-use bioprocessing revenue is projected to grow from USD 21.01 billion in 2024 to USD 54.40 billion by 2031, at a CAGR of 14.56%.
• North America led the market in 2023 with a 36.74% share, valued at USD 6.85 billion.
• Asia Pacific is expected to be the fastest-growing region, with a projected CAGR of 16.46% through 2031.
• The bags and bottles product segment generated the largest revenue in 2023, at USD 6.64 billion.
• The biopharmaceutical manufacturers end-user segment is projected to reach USD 25.94 billion by 2031.

Outlook

With biopharmaceutical manufacturers continuing to prioritize flexibility, contamination control, and cost efficiency, the single-use bioprocessing market is well positioned for sustained double-digit growth through 2031. As Asia Pacific accelerates and North America maintains its leadership position, industry participants that combine innovative product design with scalable manufacturing capacity are likely to capture the greatest share of this expanding opportunity.